AVDL Annual SG&A
$151.71 M
+$77.19 M+103.59%
31 December 2023
Summary:
As of January 23, 2025, AVDL annual selling, general & administrative expenses is $151.71 million, with the most recent change of +$77.19 million (+103.59%) on December 31, 2023. During the last 3 years, it has risen by +$119.30 million (+368.15%). AVDL annual SG&A is now at all-time high.AVDL Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL Quarterly SG&A
$40.39 M
-$7.01 M-14.79%
30 September 2024
Summary:
As of January 23, 2025, AVDL quarterly selling, general & administrative expenses is $40.39 million, with the most recent change of -$7.01 million (-14.79%) on September 30, 2024. Over the past year, it has dropped by -$907.00 thousand (-2.20%). AVDL quarterly SG&A is now -16.92% below its all-time high of $48.62 million, reached on March 31, 2024.AVDL Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL TTM SG&A
-$3.09 B
-$72.58 M-2.40%
30 September 2024
Summary:
As of January 23, 2025, AVDL TTM selling, general & administrative expenses is -$3.09 billion, with the most recent change of -$72.58 million (-2.40%) on September 30, 2024. Over the past year, it has dropped by -$3.25 billion (-2139.67%). AVDL TTM SG&A is now -15142.75% below its all-time high of $177.72 million, reached on September 30, 2024.AVDL TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +103.6% | -2.2% | -2139.7% |
| 3 y3 years | +368.1% | -13.7% | -3124.0% |
| 5 y5 years | +51.2% | -13.7% | -3124.0% |
AVDL Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +121.5% | -16.9% | +186.6% | -86.3% | at low |
| 5 y | 5-year | at high | +402.6% | -16.9% | +469.3% | -106.0% | at low |
| alltime | all time | at high | +4640.8% | -16.9% | +5322.0% | <-9999.0% | at low |
Avadel Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $40.39 M(-14.8%) | $177.72 M(+0.7%) |
| June 2024 | - | $47.41 M(-2.5%) | $176.49 M(+0.4%) |
| Mar 2024 | - | $48.62 M(+17.7%) | $175.86 M(+15.9%) |
| Dec 2023 | $151.71 M(+103.6%) | $41.30 M(+5.5%) | $151.71 M(+19.1%) |
| Sept 2023 | - | $39.16 M(-16.3%) | $127.39 M(+24.5%) |
| June 2023 | - | $46.78 M(+91.2%) | $102.32 M(+32.3%) |
| Mar 2023 | - | $24.47 M(+44.1%) | $77.35 M(+3.8%) |
| Dec 2022 | $74.52 M(+8.8%) | $16.98 M(+20.5%) | $74.52 M(-5.1%) |
| Sept 2022 | - | $14.10 M(-35.4%) | $78.56 M(-8.4%) |
| June 2022 | - | $21.80 M(+0.8%) | $85.75 M(+8.4%) |
| Mar 2022 | - | $21.64 M(+2.9%) | $79.12 M(+15.5%) |
| Dec 2021 | $68.50 M(+111.4%) | $21.03 M(-1.2%) | $68.50 M(+21.4%) |
| Sept 2021 | - | $21.28 M(+40.3%) | $56.44 M(+29.5%) |
| June 2021 | - | $15.17 M(+37.8%) | $43.58 M(+22.8%) |
| Mar 2021 | - | $11.01 M(+22.7%) | $35.50 M(+9.6%) |
| Dec 2020 | $32.41 M(+7.4%) | $8.97 M(+6.5%) | $32.41 M(+4.2%) |
| Sept 2020 | - | $8.42 M(+18.7%) | $31.09 M(+11.1%) |
| June 2020 | - | $7.09 M(-10.3%) | $27.99 M(+1.2%) |
| Mar 2020 | - | $7.91 M(+3.3%) | $27.65 M(-8.4%) |
| Dec 2019 | $30.18 M(-69.9%) | $7.66 M(+44.1%) | $30.18 M(-34.0%) |
| Sept 2019 | - | $5.32 M(-21.3%) | $45.72 M(-29.9%) |
| June 2019 | - | $6.76 M(-35.3%) | $65.23 M(-24.4%) |
| Mar 2019 | - | $10.45 M(-55.0%) | $86.32 M(-14.0%) |
| Dec 2018 | $100.36 M(+70.5%) | $23.20 M(-6.6%) | $100.36 M(+0.1%) |
| Sept 2018 | - | $24.83 M(-10.8%) | $100.22 M(+15.3%) |
| June 2018 | - | $27.84 M(+13.7%) | $86.95 M(+21.5%) |
| Mar 2018 | - | $24.49 M(+6.2%) | $71.53 M(+21.5%) |
| Dec 2017 | $58.86 M(+33.2%) | $23.06 M(+99.4%) | $58.86 M(+26.6%) |
| Sept 2017 | - | $11.56 M(-7.0%) | $46.49 M(-2.5%) |
| June 2017 | - | $12.43 M(+5.2%) | $47.67 M(+2.4%) |
| Mar 2017 | - | $11.81 M(+10.5%) | $46.53 M(+5.3%) |
| Dec 2016 | $44.18 M(+103.5%) | $10.69 M(-16.1%) | $44.18 M(+9.6%) |
| Sept 2016 | - | $12.74 M(+12.8%) | $40.30 M(+25.4%) |
| June 2016 | - | $11.29 M(+19.3%) | $32.13 M(+20.3%) |
| Mar 2016 | - | $9.46 M(+39.0%) | $26.71 M(+23.0%) |
| Dec 2015 | $21.71 M(+38.3%) | $6.81 M(+49.0%) | $21.71 M(+16.4%) |
| Sept 2015 | - | $4.57 M(-22.2%) | $18.65 M(+2.5%) |
| June 2015 | - | $5.87 M(+31.6%) | $18.18 M(+11.0%) |
| Mar 2015 | - | $4.46 M(+19.2%) | $16.38 M(+6.1%) |
| Dec 2014 | $15.70 M(+18.8%) | $3.74 M(-8.8%) | $15.43 M(-8.1%) |
| Sept 2014 | - | $4.11 M(+1.0%) | $16.78 M(+7.6%) |
| June 2014 | - | $4.07 M(+15.6%) | $15.60 M(+9.5%) |
| Mar 2014 | - | $3.52 M(-31.0%) | $14.24 M(+7.8%) |
| Dec 2013 | $13.22 M(-6.6%) | $5.09 M(+74.2%) | $13.22 M(+19.4%) |
| Sept 2013 | - | $2.92 M(+8.1%) | $11.07 M(-1.6%) |
| June 2013 | - | $2.71 M(+8.6%) | $11.25 M(-1.8%) |
| Mar 2013 | - | $2.49 M(-15.6%) | $11.46 M(-19.0%) |
| Dec 2012 | $14.15 M | $2.95 M(-5.1%) | $14.15 M(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $3.11 M(+6.7%) | $14.37 M(+3.7%) |
| June 2012 | - | $2.91 M(-43.8%) | $13.85 M(+2.9%) |
| Mar 2012 | - | $5.18 M(+63.7%) | $13.47 M(+24.6%) |
| Dec 2011 | $10.81 M(-4.6%) | $3.17 M(+22.2%) | $10.81 M(+4.8%) |
| Sept 2011 | - | $2.59 M(+2.5%) | $10.32 M(-3.2%) |
| June 2011 | - | $2.53 M(+0.1%) | $10.66 M(-2.5%) |
| Mar 2011 | - | $2.53 M(-5.5%) | $10.93 M(-3.6%) |
| Dec 2010 | $11.33 M(-15.0%) | $2.67 M(-8.8%) | $11.33 M(-10.2%) |
| Sept 2010 | - | $2.93 M(+4.8%) | $12.63 M(-1.6%) |
| June 2010 | - | $2.80 M(-4.6%) | $12.83 M(-3.7%) |
| Mar 2010 | - | $2.93 M(-26.1%) | $13.32 M(-0.1%) |
| Dec 2009 | $13.34 M(+3.3%) | $3.97 M(+26.4%) | $13.34 M(+14.7%) |
| Sept 2009 | - | $3.14 M(-4.5%) | $11.62 M(+2.1%) |
| June 2009 | - | $3.29 M(+11.6%) | $11.38 M(-3.4%) |
| Mar 2009 | - | $2.95 M(+30.8%) | $11.78 M(-8.7%) |
| Dec 2008 | $12.91 M(-22.3%) | $2.25 M(-22.3%) | $12.91 M(-10.9%) |
| Sept 2008 | - | $2.90 M(-21.4%) | $14.50 M(-7.8%) |
| June 2008 | - | $3.69 M(-9.5%) | $15.72 M(-5.2%) |
| Mar 2008 | - | $4.07 M(+6.1%) | $16.59 M(-0.2%) |
| Dec 2007 | $16.63 M(-4.3%) | $3.84 M(-6.9%) | $16.63 M(-4.2%) |
| Sept 2007 | - | $4.12 M(-9.4%) | $17.36 M(-3.6%) |
| June 2007 | - | $4.55 M(+10.8%) | $18.01 M(+2.5%) |
| Mar 2007 | - | $4.11 M(-10.1%) | $17.57 M(+6.3%) |
| Dec 2006 | $17.38 M(+19.5%) | $4.57 M(-4.4%) | $16.53 M(-13.3%) |
| Sept 2006 | - | $4.78 M(+16.4%) | $19.07 M(+10.5%) |
| June 2006 | - | $4.11 M(+33.6%) | $17.26 M(+9.8%) |
| Mar 2006 | - | $3.07 M(-56.8%) | $15.72 M(+8.1%) |
| Dec 2005 | $14.54 M(+91.0%) | $7.11 M(+139.2%) | $14.54 M(+57.3%) |
| Sept 2005 | - | $2.97 M(+15.7%) | $9.25 M(+15.0%) |
| June 2005 | - | $2.57 M(+35.6%) | $8.04 M(+5.1%) |
| Mar 2005 | - | $1.89 M(+4.5%) | $7.65 M(+0.4%) |
| Dec 2004 | $7.61 M(+27.6%) | $1.81 M(+2.9%) | $7.61 M(-19.1%) |
| Sept 2004 | - | $1.76 M(-19.1%) | $9.41 M(+4.7%) |
| June 2004 | - | $2.18 M(+17.2%) | $8.99 M(+10.3%) |
| Mar 2004 | - | $1.86 M(-48.5%) | $8.15 M(+11.6%) |
| Dec 2003 | $5.97 M(+48.5%) | $3.61 M(+169.4%) | $7.31 M(+41.2%) |
| Sept 2003 | - | $1.34 M(0.0%) | $5.18 M(+13.0%) |
| June 2003 | - | $1.34 M(+32.4%) | $4.58 M(+41.4%) |
| Mar 2003 | - | $1.01 M(-31.6%) | $3.24 M(+45.5%) |
| Dec 2002 | $4.02 M(+17.7%) | $1.48 M(+98.8%) | $2.23 M(+198.8%) |
| Sept 2002 | - | $745.00 K(-17.2%) | $745.00 K(-17.2%) |
| Dec 2001 | $3.41 M(-1.2%) | - | - |
| Dec 2000 | $3.46 M(-6.4%) | - | - |
| Dec 1999 | $3.69 M(+1.7%) | - | - |
| Dec 1998 | $3.63 M(+13.5%) | - | - |
| Mar 1998 | - | $900.00 K(-71.0%) | $900.00 K(-71.0%) |
| Dec 1997 | $3.20 M(-74.6%) | - | - |
| Dec 1996 | $12.60 M | - | - |
| Mar 1996 | - | $3.10 M | $3.10 M |
FAQ
- What is Avadel Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals annual SG&A year-on-year change?
- What is Avadel Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals quarterly SG&A year-on-year change?
- What is Avadel Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals TTM SG&A year-on-year change?
What is Avadel Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of AVDL is $151.71 M
What is the all time high annual SG&A for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high annual selling, general & administrative expenses is $151.71 M
What is Avadel Pharmaceuticals annual SG&A year-on-year change?
Over the past year, AVDL annual selling, general & administrative expenses has changed by +$77.19 M (+103.59%)
What is Avadel Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of AVDL is $40.39 M
What is the all time high quarterly SG&A for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $48.62 M
What is Avadel Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, AVDL quarterly selling, general & administrative expenses has changed by -$907.00 K (-2.20%)
What is Avadel Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of AVDL is -$3.09 B
What is the all time high TTM SG&A for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high TTM selling, general & administrative expenses is $177.72 M
What is Avadel Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, AVDL TTM selling, general & administrative expenses has changed by -$3.25 B (-2139.67%)